ARTICLE | Clinical News
IDD-3: Began Phase II testing
February 5, 2001 8:00 AM UTC
Immuno-Designed Molecules S.A., Paris, France Product: IDD-3 Business: Cancer Therapeutic category: Immune stimulation Target: Immune cells Description: Autologous dendritic cells loaded with tumor an...